Bionano Genomics
BNGO

$0.4799

5.47%

Market Cap: $41.3M

About: Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in Americas, EMEA and Asia Pacific; majority revenue being generated from Americas. They generate product revenue from sales of its OGM and Ionic Purification systems and consumables, which includes its instruments, and their VIA software.

Employees: 344

Industrials Laboratory Analytical Instruments

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

67% more call options, than puts

Call options by funds: $77K | Put options by funds: $46K

0.5% more ownership

Funds ownership: 9.06% [Q1] → 9.56% (+0.5%) [Q2]

5% less funds holding

Funds holding: 61 [Q1] → 58 (-3) [Q2]

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

18% less capital invested

Capital invested by funds: $5.49M [Q1] → $4.48M (-$1.01M) [Q2]

21% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 14

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$1

108%

upside

Avg. target

$1

108%

upside

High target

$1

108%

upside

1 analyst rating

0 positive

0%

1 neutral

100%

0 negative

0%

Scotiabank

Sung Ji Nam

54% 1-year accuracy

7 / 13 met price target

108%upside

$1

Sector Perform

Downgraded

28 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about BNGO published over the past 30 days

Zacks Investment Research

Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now

Bionano Genomics (BNGO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Bionano Genomics (BNGO), Here's Why It's a 'Buy' Now

Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)

Bionano Genomics, Inc. (NASDAQ:BNGO ) Canaccord Genuity 44th Annual Growth Results Conference August 13, 2024 3:30 PM ET Company Participants Erik Holmlin - President and Chief Executive Officer Conference Call Participants Kyle Mikson - Canaccord Genuity Kyle Mikson Hi. Welcome to the Canaccord Genuity Global Growth Conference.

Bionano Genomics, Inc. (BNGO) Canaccord Genuity 44th Annual Growth Conference (Transcript)

Zacks Investment Research

Bionano Genomics (BNGO) Upgraded to Buy: Here's Why

Bionano Genomics (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Bionano Genomics (BNGO) Upgraded to Buy: Here's Why

Bionano Genomics, Inc. (BNGO) Q2 2024 Earnings Call Transcript

Bionano Genomics, Inc. (NASDAQ:BNGO ) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants David Holmes - Investor Relations Erik Holmlin - President & Chief Executive Officer Gülsen Kama - Chief Financial Officer Conference Call Participants Destiny Hance - Ladenburg Thalmann & Co. Operator Good day and thank you for standing by. Welcome to the Bionano Q2 Financial Results Call.

Bionano Genomics, Inc. (BNGO) Q2 2024 Earnings Call Transcript

Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress

Q2 2024 revenue was $7.8 million, which represents a 10% decrease from Q2 2023 Total installed base of 363 optical genome mapping (OGM) systems as of Q2 2024, which represents a 29% increase over Q2 2023 Sold 6,165 nanochannel array flowcells in Q2 2024, which represents a 13% decrease from the number of flowcells sold in Q2 2023 The editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT®) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies Conference call today, August 7th, 2024 at 4:30 PM ET SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2024. “We saw positive growth in the OGM installed base this quarter, along with key advancements to our VIA software and the achievement of a significant milestone with the establishment of a Category I CPT code for OGM, which we believe will raise the awareness and utility of OGM,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress

Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference

SAN DIEGO, July 31, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano's president and chief executive officer, will present at the Canaccord Genuity 44th Annual Growth Conference on August 13, 2024.

Bionano to Present at the Canaccord Genuity 44th Annual Growth Conference

Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants

Bionano Announces Closing of up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

$10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants $10 million upfront with up to an additional $20 million upon the exercise in full of clinical milestone-linked Series Warrants

Bionano Announces up to $30 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Scientific Presentations Highlight OGM's Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations

SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Bionano Laboratories, a clinical laboratory services business of Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that optical genome mapping (OGM) will be featured in three scientific presentations at the 2024 joint annual meeting for the American Society for Clinical Laboratory Science (ASCLS), the Association of Genetic Technologists (AGT), and the Society of American Federal Medical Laboratory Scientists (SAFMLS). The conference, which brings together laboratory professionals and industry partners affiliated with three professional societies for networking and educational sessions focused on chemistry, microbiology, hematology, molecular diagnostics and cytogenetics, will be held July 8-12, 2024, in Pittsburgh, Pennsylvania and online.

Scientific Presentations Highlight OGM's Utility for Cancer Research at Joint Annual Meeting for Three Molecular and Cytogenetic Associations

Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research

Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano's VIA™ software to Revvity's next generation sequencing (NGS) customers as part of its newborn sequencing research workflow VIA is expected to enhance Revvity's newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow's interpretation capabilities SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE: RVTY) under which Revvity will market and commercialize Bionano's VIA™ software as part their newborn sequencing research workflow. VIA is expected to enhance the comprehensive reporting capabilities of Revvity's sequencing solution by adding an assessment of CNVs to its NGS workflow and streamlining the workflow's interpretation capabilities.

Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research

See News Rankings